These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

751 related articles for article (PubMed ID: 29389859)

  • 1. Role of Galectins in Tumors and in Clinical Immunotherapy.
    Chou FC; Chen HY; Kuo CC; Sytwu HK
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29389859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lactulose as a novel template for anticancer drug development targeting galectins.
    Kishor C; Ross RL; Blanchard H
    Chem Biol Drug Des; 2018 Oct; 92(4):1801-1808. PubMed ID: 29888844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of galectins in cancer: a critical review.
    van den Brûle F; Califice S; Castronovo V
    Glycoconj J; 2002; 19(7-9):537-42. PubMed ID: 14758077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Varied expression and localization of multiple galectins in different cancer cell lines.
    Satelli A; Rao PS; Gupta PK; Lockman PR; Srivenugopal KS; Rao US
    Oncol Rep; 2008 Mar; 19(3):587-94. PubMed ID: 18288388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thermodynamic binding studies of galectin-1, -3 and -7.
    Brewer CF
    Glycoconj J; 2002; 19(7-9):459-65. PubMed ID: 14758069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mesenchymal stem cell-mediated T cell suppression occurs through secreted galectins.
    Sioud M; Mobergslien A; Boudabous A; Fløisand Y
    Int J Oncol; 2011 Feb; 38(2):385-90. PubMed ID: 21165555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Galectin signatures contribute to the heterogeneity of breast cancer and provide new prognostic information and therapeutic targets.
    Grosset AA; Labrie M; Vladoiu MC; Yousef EM; Gaboury L; St-Pierre Y
    Oncotarget; 2016 Apr; 7(14):18183-203. PubMed ID: 26933916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluorescence polarization as an analytical tool to evaluate galectin-ligand interactions.
    Sörme P; Kahl-Knutsson B; Huflejt M; Nilsson UJ; Leffler H
    Anal Biochem; 2004 Nov; 334(1):36-47. PubMed ID: 15464951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Galectins-1, -3, and -7 Are Prognostic Markers for Survival of Ovarian Cancer Patients.
    Schulz H; Schmoeckel E; Kuhn C; Hofmann S; Mayr D; Mahner S; Jeschke U
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28594391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Galectins in Multiple Myeloma.
    Storti P; Marchica V; Giuliani N
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29258207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psoriasis in humans is associated with down-regulation of galectins in dendritic cells.
    de la Fuente H; Perez-Gala S; Bonay P; Cruz-Adalia A; Cibrian D; Sanchez-Cuellar S; Dauden E; Fresno M; García-Diez A; Sanchez-Madrid F
    J Pathol; 2012 Oct; 228(2):193-203. PubMed ID: 22271227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Galectin-9 binds to O-glycans on protein disulfide isomerase.
    Schaefer K; Webb NE; Pang M; Hernandez-Davies JE; Lee KP; Gonzalez P; Douglass MV; Lee B; Baum LG
    Glycobiology; 2017 Sep; 27(9):878-887. PubMed ID: 28810662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-type-specific expression of murine multifunctional galectin-3 and its association with follicular atresia/luteolysis in contrast to pro-apoptotic galectins-1 and -7.
    Lohr M; Kaltner H; Lensch M; André S; Sinowatz F; Gabius HJ
    Histochem Cell Biol; 2008 Sep; 130(3):567-81. PubMed ID: 18597104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Galectin inhibitory disaccharides promote tumour immunity in a breast cancer model.
    Stannard KA; Collins PM; Ito K; Sullivan EM; Scott SA; Gabutero E; Darren Grice I; Low P; Nilsson UJ; Leffler H; Blanchard H; Ralph SJ
    Cancer Lett; 2010 Dec; 299(2):95-110. PubMed ID: 20826047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unraveling galectin-1 as a novel therapeutic target for cancer.
    Astorgues-Xerri L; Riveiro ME; Tijeras-Raballand A; Serova M; Neuzillet C; Albert S; Raymond E; Faivre S
    Cancer Treat Rev; 2014 Mar; 40(2):307-19. PubMed ID: 23953240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Taloside inhibitors of galectin-1 and galectin-3.
    Collins PM; Oberg CT; Leffler H; Nilsson UJ; Blanchard H
    Chem Biol Drug Des; 2012 Mar; 79(3):339-46. PubMed ID: 22136701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Degraded Arabinogalactans and Their Binding Properties to Cancer-Associated Human Galectins.
    Pfeifer L; Baumann A; Petersen LM; Höger B; Beitz E; Classen B
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Quantitative Human Red Blood Cell Agglutination Assay for Characterisation of Galectin Inhibitors.
    Gasson R; Roper JA; Slack RJ
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Context-dependent multifunctionality of galectin-1: a challenge for defining the lectin as therapeutic target.
    Smetana K; André S; Kaltner H; Kopitz J; Gabius HJ
    Expert Opin Ther Targets; 2013 Apr; 17(4):379-92. PubMed ID: 23289445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Galectin-loaded cells as a platform for the profiling of lectin specificity by fluorescent neoglycoconjugates: a case study on galectins-1 and -3 and the impact of assay setting.
    Rapoport EM; André S; Kurmyshkina OV; Pochechueva TV; Severov VV; Pazynina GV; Gabius HJ; Bovin NV
    Glycobiology; 2008 Apr; 18(4):315-24. PubMed ID: 18256179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.